8th Plenary Meeting EHDN 2014 Barcelona: 19-21 settembre 2014 – Report

Annarita Bentivoglio* - Marina Frontali** Si è appena concluso l’ottavo meeting plenario del Network Europeo per la Malattia di Huntington. Oltre 900 partecipanti: l’incontro più numeroso...

Fatal cellular malfunction identified in Huntington’s disease

Researchers believe they have learned how mutations in the gene that causes Huntington’s disease kill brain cells, a finding that could open new opportunities...

New roles for huntingtin: removing a healthy protein to understand its...

This article was first published at en.hdbuzz.net Some techniques aimed at lowering mutant huntingtin can also affect the normal form of the protein. With clinical...

GLOBAL HUNTINGTON’S DISEASE PATIENT ADVOCACY ORGANIZATIONS UNITE TO FORM HUNTINGTON’S DISEASE...

This article was first published at www.hdsa.org The European Huntington Association (EHA), Huntington’s Disease Society of America (HDSA) and Huntington Society of Canada (HSC) are...

BioSensics™ Has Received over $2.5M in Grant Funding from the NIH...

BioSensics, a leader in developing wearable sensor technologies for clinical research and medical applications, has received grant funding from the National Institutes of Health...

George Yohrling, Ph.D Discusses Current and Potential HD Treatment Options

Since 2012, George Yohrling, PhD has served as the Senior Director, Mission and Scientific Affairs for the Huntington’s Disease Society of America (HDSA). In...

C-Path, CHDI, and CDISC Announce Public Review for Huntington’s Disease Therapeutic...

TUCSON, AZ, NEW YORK, NY, and AUSTIN, TX – September 11, 2017 – Critical Path Institute (C-Path), CHDI Foundation, Inc. (CHDI), and The Clinical Data Interchange Standards Consortium (CDISC) announce...

Quanterix to Host Webinar on Predicting the Progression of Neurodegeneration with...

Press Release  Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it is hosting...

A thiol probe for measuring unfolded protein load and proteostasis in...

Abstract When proteostasis becomes unbalanced, unfolded proteins can accumulate and aggregate. Here we report that the dye, tetraphenylethene maleimide (TPE-MI) can be used to measure...

Precision huntingtin-lowering drug trials target the mutant protein

A new exciting chapter in Huntington’s disease (HD) treatment is just beginning – WAVE Life Sciences have announced PRECISION-HD1 and 2, clinical trials of...

A step forward for gene editing: CRISPR-Cas9 and HD

CRISPR-Cas9 is an experimental gene editing technique used to make precise changes in DNA. For the first time, scientists have used this approach to...

Huntington’s Disease: An Interview with Dr. Burton Scott

Huntington’s disease is a genetic neurodegenerative disease that can have a devastating effect on a patient – physically, psychologically, and cognitively. Chorea is the...

Potential treatment for Huntington’s disease discovered by NUIG researchers

Collaboration with University of Barcelona aims to find cure for ‘relentlessly fatal’ condition Researchers at NUI Galway have discovered what they say are encouraging early signs for...

Cost-Effective Way to Diagnose Huntington’s Disease Coming to Microsoft’s Imagine Cup

With imagination, creativity and a little bit of help from Microsoft, 3 university students have discovered a way to identify and diagnose Huntington’s disease...

BIG PHARMA BUYS INTO CROWDSOURCING FOR DRUG DISCOVERY

HUNTINGTON’S DISEASE IS brutal in its simplicity. The disorder, which slowly bulldozes your ability to control your body, starts with just a single mutation, in...

Wave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 and...

Trials Evaluate the First Allele-Specific Investigational Drugs for Huntington’s Disease, WVE-120101 and WVE-120102  Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies...

New data network for Huntington’s disease research

Scientists searching for a cure for Huntington's disease now have free access to the first data network relating to the disease Huntington’s disease is an...

Teva and the Huntington Study Group Announce Publication of Data for...

Data support overnight conversion from tetrabenazine to AUSTEDO™ for the treatment of chorea associated with Huntington disease JERUSALEM--(BUSINESS WIRE)--Jul. 11, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and...

Scientists deploy GM sheep in fight to treat Huntington’s disease

Transgenic flock brought to UK for research into incurable brain condition, which affects more than 6,700 people in the country Scientists at Cambridge University have...

Long-term Safety of Deutetrabenazine for Chorea Confirmed

Deutetrabenazine used to treat chorea in patients with Huntington's disease (HD) continues to be safe over the long term, with stabilization of motor symptoms...

Can CRISPR Conquer Huntington’s?

I set a high bar for writing about mouse studies. I don’t include them in my textbooks or news articles, and only rarely blog...

Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with...

Press Release Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease Completed and Open-Label Extension Study to Open in 2H 2017 CARLSBAD,...